

**Listing of Claims:**

1-14. (Canceled)

15. (Previously Presented) A method of treating a patient suffering from an elevated blood level of ionized calcium accompanied by cachexia caused by interleukin-6 (IL-6) production comprising administering to said patient a therapeutically effective amount of an antibody to an IL-6 receptor in a pharmaceutically acceptable carrier to suppress elevation of blood level of ionized calcium and wherein the therapeutically effective amount blocks signal transduction by IL-6 and inhibits the binding of IL-6 to the IL-6 receptor.

16 -23. (Canceled)

24. (Previously Presented) The method according to claim 15, wherein said antibody is a monoclonal antibody.

25. (Previously Presented) The method according to claim 24, wherein said monoclonal antibody is the PM-1 antibody produced by hybridoma PM-1, accession number FERM BP-2998.

26. (Previously Presented) The method according to claim 24, wherein said monoclonal antibody is a chimeric antibody comprising the variable immunoglobulin heavy and light chains from a murine monoclonal antibody to an IL-6 receptor and the constant immunoglobulin heavy and light chains from a human monoclonal antibody.

27. (Previously Presented) The method according to claim 24, wherein said monoclonal antibody is a humanized murine monoclonal antibody to an IL-6 receptor.

28. (Previously Presented) The method according to claim 27, wherein said humanized murine monoclonal antibody to an IL-6 receptor is a humanized PM-1 antibody, wherein the PM-1 antibody prior to humanization is produced by hybridoma PM-1, accession number FERM BP-2998.